Relapse of COVID-19-associated mucormycosis in patients receiving posaconazole as maintenance treatment
Our findings showed a significant relapse of CAM (9%). A longer duration of posaconazole consumption and completion of treatment for initial orbital involvement in CAM patients are recommended for better patient management and prevention of relapse.
Authors
- Hasti Kamali Sarvestani (ORCID: https://orcid.org/0000-0002-5431-5468)
- Azin Tabari (ORCID: https://orcid.org/0000-0003-0097-7148)
- Kazem Ahmadikia (ORCID: https://orcid.org/0000-0003-1745-196X)
- Elahe Samiee Fard
- Sadegh Khodavaisy (ORCID: https://orcid.org/0000-0001-8039-4991)
- Marzieh Darvishi (ORCID: https://orcid.org/0000-0001-7656-0854)
- Farzad Pakdel (ORCID: https://orcid.org/0000-0001-7392-6056)
- Zahra Rafat (ORCID: https://orcid.org/0000-0002-8905-1634)
- Mohammadreza Salehi (ORCID: https://orcid.org/0000-0002-5538-7586)
- Abolfazl Sobati (ORCID: https://orcid.org/0000-0003-0440-5761)
- Cristina Mussini (ORCID: https://orcid.org/0000-0002-6615-4198)
- Mehrdad Shavandi (ORCID: https://orcid.org/0000-0001-9459-3457)
Institutions
- University of Modena and Reggio Emilia (IT)
- Guilan University of Medical Sciences (IR)
- Imam Khomeini Hospital (IR)
- Khatam University (IR)
- Farabi Hospital (IR)
- Shaheed Rajaei Cardiovascular Medical and Research Center (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- The Journal of Infection in Developing Countries
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3855/jidc.19645
- Citations
- 1
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Tehran University of Medical Sciences and Health Services